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Abstract
Cancer progression is mediated by processes that are also important in wound repair. As a result,
cancers have been conceptualized as overhealing wounds or wounds that do not heal, and gene
expression signatures reflective of wound repair have shown value as predictors of breast cancer
survival. Despite the widespread acknowledgment of commonalities between host responses to
wounds and host responses to cancer, the gene expression responses of normal tissue adjacent to
cancers have not been well characterized. Using RNA extracted from histologically normal breast
tissue from 107 patients, including 60 reduction mammoplasty patients and 47 cancer patients, we
measured whole genome expression profiles and identified a gene expression signature that is
induced in response to breast cancer. This signature represents an in vivo wound response signature
that is differentially expressed in the normal tissue of breast cancer patients compared to those without
disease and is highly accurate (at least 92% sensitivity and 98% specificity) in distinguishing diseased
and nondiseased. The in vivo wound response signature is highly prognostic of breast cancer survival
and there is a strong association between the groups identified by this signature and those identified
using serum-treated fibroblasts and other microenvironment-derived or -related signatures. The
prevalence of the wound response signature in histologically normal tissue adjacent to breast cancer
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Statement of Translational Relevance
These data show that wound responses are activated in the gene expression profile of normal tissue adjacent to cancer and that this in
vivo wound response signature predicts prognosis in independent tumor datasets. If normal tissue adjacent to breast cancer expresses
genomic signatures with promoting characteristics, surgical interventions may need to evaluate wider margins consistent with the
geographic range of these alterations. Furthermore, differential expression of wound response signatures across different tumors and
tumor subtypes suggests that individualized targeting of microenvironment may be a viable treatment strategy in breast cancer. For
example, significant heterogeneity in extracellular matrix (ECM) or angiogenesis gene expression may suggest differential efficacy of
ECM- or angiogenesis-targeted drugs. These studies provide support for the notion that the normal microenvironment is an important
variable in breast cancer progression and may be an important target for future clinical interventions.
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suggests that microenvironment response is an important variable in breast cancer progression and
may be an important target for clinical interventions.
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INTRODUCTION
The concept of cancers as “wounds that do not heal” arose more than twenty years ago based
on the observation of gross cellular and molecular similarities between wounds and cancer
tissue (1,2). Wound response involves clotting and coagulation, tissue remodeling, cellular
migration and proliferation, and angiogenesis. Many of these processes have well recognized
roles in promoting cancer. Thus, the hypothesis that tumors induce wound responses in cancer
microenvironments has been the subject of recent reviews (2), and has led to suggestions that
targeting the microenvironment could lead to new cancer therapies (3,4) or chemoprevention
opportunities (5). Other targets and drugs in the microenvironment have not been successful
[reviewed in (6)], highlighting the need to better characterize of the microenvironment response
to breast cancer.
The gene expression alterations present in the breast cancer microenvironment have been
examined in a few previous studies. In a careful study by Allinen et al. (7), pure cell populations
were isolated from two reduction mammoplasty, two ductal carcinoma in situ, and 10 invasive
breast cancer patients. Serial analysis of gene expression (SAGE) of these purified cell
populations documented widespread molecular changes in all cell types of breast cancer stroma
(7). These molecular changes may reflect paracrine interactions among the diverse cell types
that are present in the mammary gland during carcinogenesis: progression to carcinoma is
associated with increases in myofibroblasts and immune cells, as well as increased
vascularization (8–13). However, recent studies comparing stroma from reduction
mammoplasty patients to stroma adjacent to breast cancers failed to identify any gene
expression changes associated with disease status (14). Technical differences between these
two studies may account for their distinct conclusions. Further research is needed to explain
differences between these two studies. Since both studies relied on relatively small numbers
of patients, little is known about interindividual variation in the microenvironment response.
However, previous studies of breast cancers suggest that interindividual variation is an
important feature of cancer-associated wound responses: based on the idea that fibroblasts in
vivo are exposed to serum only during wounding, Chang et al. (15) used cultured fibroblasts
from many different anatomical sites to derive a “wound response” signature, that is highly
prognostic in breast cancer patients (15). Whether that signature is altered in the
microenvironment adjacent to breast cancer has not been evaluated previously.
We hypothesized that with larger sample sizes, a reproducible gene expression signature of
activated wound response would be detectable in vivo in the microenvironment of breast cancer.
We used whole genome microarrays to investigate gene expression in 107 patients, including
60 reduction mammoplasty (RM) patients and 47 histologically normal samples from cancer
patients (referred to as cancer-adjacent normal, or CN samples). Our results show that an in
vivo wound response signature is identifiable in the histologically normal tissue adjacent to
breast cancer and that this signature has strong predictive value in distinguishing normal tissue
of cancer patients from that of disease free individuals. This signature is also prognostic,
confirming the importance of wound response in breast cancer progression.
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Patients were women undergoing elective reduction mammoplasty (RM) at Baystate Medical
Center in Springfield, Massachusetts or mastectomy at University of North Carolina Hospitals
in Chapel Hill, NC. All patients enrolled voluntarily under Institutional Review Board
approved protocols. RM tissue was excluded if pathological assessment of patient-matched
paraffin embedded tissues suggested any abnormal malignant or pre-malignant findings. For
histologically normal tissue adjacent to breast cancer (CN), a pathologist from the Tissue
Procurement Facility (TPF) at University of North Carolina at Chapel Hill confirmed
histologically normal tissues. Only patients receiving no neoadjuvant therapy prior to surgery
were included. All tissues were handled by snap freezing immediately after surgery and RNA
was isolated using a single protocol as described in Hu et al. (16).
Microarrays
All microarrays were performed at the University of North Carolina at Chapel Hill. Two-color
Agilent human arrays were used. Cy3-labeled reference was produced from total RNA from
Stratagene Universal Human Reference (spiked with 1:1000 with MCF-7 RNA and 1:1000
with ME16C RNA to increase expression of breast cancer genes) following amplification with
Agilent’s low RNA input amplification kit. The identical protocol was applied to total RNA
from RM or CN tissue, but the patient samples were labeled with Cy5. Some samples from
RM and CN groups were performed on 4X44k Agilent whole genome arrays and some of each
type were performed on 244k Agilent custom arrays that included all of the probes from the
4by44K array. Only probes that were present on both formats were utilized in the final analysis
and intraclass correlation coefficients for technical replicates assayed on the same platform
(range: 0.73 – 0.97, median 0.89, n=8) did not show meaningful differences from those
conducted on different platforms (range: 0.708 – 0.938, median 0.90, n=12). Principal
component analysis (PCA) suggested no substantial difference between the two platforms.
Duplicate microarrays corresponding to the same patient sample were combined by averaging.
All data are publicly available through the Gene Expression Omnibus (GSEXXXX, in
progress).
Data Normalization and Age-Adjustment
Data were lowess normalized and only genes with signal intensity >10 in both channels were
included in analyses. Because the RM patients tended to be younger than the CN patients, we
selectively adjusted for confounding by age using the following algorithm: First, we estimated
the effect of tissue type (RM vs. CN) in a linear regression model that included tissue type as
a main effect and age as a covariate (full model). We compared the main effect estimate from
this full model to that of a reduced model that included only the main effect (no age parameter).
We concluded that age was a confounder if inclusion of age in the model induced a change in
the main effect parameter greater than 10% and that change-in-effect was in the top 80th
percentile. To ensure that the change-in-effect estimate was stable, we performed 100 bootstrap
samplings and confirmed that genes were similarly affected in the original analysis and in the
bootstrap analysis. That is, in the majority of cases those genes that were unadjusted in the
original data remained unadjusted in the bootstrap. We utilized the parameter estimates from
the original analysis to select genes for age-adjustment, and as a result, we adjusted for age in
19% of genes. This is concordant with previous literature from lymphoblastoid cell lines
suggesting that at least 10% of genes were significantly associated with donor age (17).
Identical normalization parameters and age-adjustment parameters and algorithms applied to
the training set were used to adjust for age in the test set.
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The age-adjusted training dataset was analyzed using Distance Weighted Discrimination to
identify genes that distinguished RM and CN samples (18). The top 200 DWD loadings were
selected for the predictive signature based upon the observation that this was the smallest gene
set that provided maximum predictive accuracy in the training set (by ten-fold cross validation).
Average predictive accuracy in 10-fold cross validation was 95.4% (95% CI: 95.1%–96.3%)
in the training data set, with 91.9% sensitivity (95%CI: 91.2%–94.1%) and 97.98% specificity
(95%CI: 97.92%–97.92%) and the same set of genes was used to assign class membership in
the test set.
To evaluate the Chang et al. (15) serum response as a predictor of CN vs. RM status, all patients
in the training set were classified according to the Pearson correlation of its expression levels
of the Core Serum Response (CSR) genes to the serum activated fibroblast centroid. Patients
with correlation >−0.15 were classified as “activated” and patients with correlation ≤−0.15
were classified as “quiescent”, as described in the original paper.
Prediction of Breast Cancer Survival
To evaluate the prognostic value of our signature, we used published gene expression data for
breast tumors from 295 patients, derived by researchers from Netherlands Cancer Institute
(NKI) and Rosetta Inpharmatics-Merck using Agilent oligonucleotide microarrays (15,19,
20). To evaluate the prognostic value of our in vivo wound response signature, we mapped our
200 probes, representing 155 genes, to 112 genes on the NKI dataset. We then used PCA to
define three groups of equal size. These groups were then evaluated in univariate Kaplan-Meier
analyses using WinSTAT. We compared our prognostic signature to the wound response
signature published for these tumors by Chang et al. (15). For that comparison, we used the
group definitions from the original paper (two groups, Activated and Quiescent). In addition,
we compared our signature to the Stroma-Derived Prognostic Predictor (SDPP) of Finak et al.
(21) and the 66 gene desmoids-type fibromatosis (DTF) signature (22), both of which were
used to define three groups of equal size by PCA.
Immunohistochemistry
A series of CN (n=7) and RM (n=8) samples that had been analyzed by microarray were also
analyzed by immunohistochemistry. Five-micron sections cut from formalin-fixed paraffin-
embedded tissue blocks were deparaffinized and rehydrated following standard protocol.
Sections were incubated with antisera against COX-2 (Cayman Chemical) and CYR61 (H-78,
Santa Cruz) following manufacturers’ instructions. Antigen-antibody complexes were
visualized using horseradish peroxidase labeled polymer kit following standard protocol
(DAKO). Sections were counterstained in hematoxylin dehydrated through graded alcohols,
cleared in xylene, and mounted in permount.
RESULTS
Activated Wound Responses in Normal Tissue Adjacent to Breast Cancer
Using data from 48 reduction mammoplasty (RM) samples and 34 histologically normal
samples adjacent to cancer (CN), we performed Distance Weighted Discrimination to select
the top 200 probes that were differentially expressed between RM and CN patients. In ten fold
cross validation, these 200 probes, representing 155 genes had 98% accuracy in predicting RM
vs. CN status. Figure 1 shows a hierarchical cluster of these 82 patients using this gene list
(complete gene list and values for all 200 probes shown in Supplemental Table 1).
The CN signature appears to be enriched for many genes previously shown to have an important
role in wound healing and inflammation (Figure 1, Supplemental Table 2). For example,
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extracellular matrix (ECM) deposition is an important process in repairing of wounds and ECM
genes are differentially expressed between RM and CN samples. Figure 1C shows a group of
genes more highly expressed in RM tissue than in CN tissue that includes genes in the Gene
Ontology categories for extracellular matrix such as EGFL6, BMPER, ELA2, and TFPI2.
TFPI2 is the negative regulator of F3, and consistent with lower expression of its inhibitor, the
transcript levels of F3 are higher in CN samples (Figure 1D), along with a number of other
genes involved in extracellular matrix formation such as ADAMTS4, OGN, PDGFRL,
FBLN1, LUM, EFEMP1. Thus, clusters 1C and 1D show dysregulation of ECM in the
microenvironment of cancer. Functional annotation clustering with DAVID
(http://david.abcc.ncifcrf.gov/) shows ECM genes are significantly overrepresented in our in
vivo signature for response to cancer (Supplemental Table 2). Three functional annotation
clusters including extracellular matrix genes were identified with GO terms such as
extracellular region (Benjamini p=1.0e-11), extracellular region part (2.7e-8) and extracellular
matrix (3.7e-4) statistically overrepresented. Supplemental Table 2 shows DAVID functional
annotation clustering results.
Angiogenesis is an important process in wound healing. Consistent with a role for angiogenesis
in the cancer microenvironment, Figure 1E includes important immediate early (IE)
angiogenesis genes such as PTGS2/COX-2, CYR61 and CTGF (23–26). Furthermore, well-
documented binding partners for CYR61 and CTGF (including THBS1 and BMPER) are
upregulated in CNs. Thus, these pathways and the CCN family of genes may be important in
regulating the host response to cancer. Both PTGS2 and CTGF are immediate early genes that
are in the GO category “response to wounding”, which was enriched in our data (p=1.4e-5),
and the role of CYR61 in wound response is well established in recent literature (27). PTGS2
has been previously shown to be elevated in the microenvironment of breast cancer (28). Figure
1E therefore represents an important wound response angiogenic signature that is activated in
the breast cancer microenvironment.
Genes from the GO “cellular adhesion” category were represented in Figure 1F, including
LAMA3 and LAMC2. The cluster in Figure 1F also included a number of chemotaxis genes
such as IL1B, CXCL1, and CXCL14, the latter of which has previously been shown to be
upregulated in the histologically normal tissue of breast cancer patients (7). Figure 1G includes
a wide range of genes involved in re-epithelialization after wounding, including keratins 6A,
6B, 6C and 14, 14p, 16 (29–31). Re-epithelialization is one of the major processes necessary
for successful wound repair (32). Keratins are overrepresented in our functional clusters
(p=5.2e-5), in a cluster that includes significant enrichment for GO categories epidermis
development (p=2.8e-4), ectoderm development (p=2.8e-4) and cell communication
(p=5.5e-6). Figure 1G shows overrepresentation of cellular adhesion genes, including TP63
(33), DST, COL17A1, DSC3. In sum, Figures 1F and 1G show remodeling clusters that are
dependent upon paracrine signaling and heterotypic interactions between cell types. Taken as
a whole, Figure 1 demonstrates that the wound healing processes that have been well
documented in skin (32) are strongly induced in the microenvironment of normal breast tissue
adjacent to breast cancers.
The original work hypothesizing that tumors resemble chronic wounds was referring to the
tumor stroma rather than the adjacent normal tissue (1). While we defined a wound response
signature in adjacent normal tissue, we were interested to examine the relative expression of
this signature in the tumors themselves. Supplemental Figure 1 depicts the expression of the
200 probes across the 82 patients, including the paired tumor tissue for each of the cancer
patients, with the groups of genes labeled according to the corresponding clusters from Figure
1. This figure shows that for some clusters (e.g. Figure 1C) where CN has lower expression
than RM, the decreased expression is even more pronounced in the tumors. Likewise, many
of the genes in Figure 1F that were upregulated in CN are more strongly upregulated in tumors.
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However, there are groups of genes from Figure 1D–F that are homogeneously expressed in
CN tissue, and heterogeneous expression in tumors, and there are genes (eg. Figure 1G), that
are upregulated in CN and expressed at lower levels in tumors. In the case of the cluster in
Figure 1G, many of these genes are immune response/chemotaxis genes and therefore
downregulation in the immunosuppressive tumor microenvironment, but not the adjacent
normal, may be expected. In sum, our gene list has a unique expression profile in each of the
tissue types (CN vs. RM vs. tumor) consistent with some of the known biological features of
each tissue type, and our signature reliably segregates normal breast samples from patients
with disease from those without disease (Figure 1B and dendrogram in Supplemental Figure
1).
Localization of PTGS2/COX-2 and CYR61 by Immunohistochemistry
To confirm the changes that we observed by microarray and to identify the cell types
responsible for altered expression, we performed immunohistochemistry for two markers from
the Angiogenesis/IE cluster in Figure 1E. Representative images are shown in Supplemental
Figure 2. COX-2 was more highly expressed in the luminal epithelium of CN patients than
RM patients (two-tailed t-test with unequal variance, p=0.0005), consistent with previous
observations (28). Less than half of the RM samples (5 of 13) were positive for COX-2 staining,
with average score of 0.7 (range from 1 to 2). However, 16 of 18 (89%) of cancer-adjacent
normal samples were positive for COX-2, with an average score of 2.1 (range from 1 to 3).
CYR61 was moderately or strongly expressed in the luminal epithelium of both CN and RM
patients, and we also observed CYR61 expression in fibroblasts, endothelial cells, plasma cells,
and lymphocytes. Thus, the 2–4 fold change in CYR61 RNA levels in CN relative to RM may
reflect changes in expression levels of specific cellular populations or may reflect changes in
the distribution of cell types present in the tissue.
Predictive Accuracy of the Wound Response Signature
Our in vivo wound response signature distinguished CN samples from RM samples with 98%
accuracy in the training set, with 94% sensitivity and 100% specificity. This accuracy and the
striking expression differences between CN and RM shown in Figure 1 suggest that this
signature can be used to predict the disease status of histologically normal samples in an
independent test set. To our knowledge, there are no comparable, publicly available dataset of
grossly dissected human breast tissue, and therefore we collected a separate test set of 25
additional arrays (12 RM and 13 CN). In this independent test set, we correctly predicted CN
vs. RM status with 96% accuracy (92% sensitivity and 100% specificity), with only one of 13
CN samples incorrectly classified as an RM.
The population undergoing RM surgery may be systematically different from general
population. While some women undergo unilateral RM for cosmetic reasons, others undergo
bilateral RM to address ergonomic problems. This latter group may have more fatty tissue and
larger breasts, and therefore it is possible that some of these patients have biology that differs
from normal breast biology in the general population. To evaluate generalizability of our study,
we obtained a second test set comprised of ten additional samples of normal breast tissue, none
of which were from reduction mammoplasty patients: three normal breast samples from women
with benign diagnoses (1 benign cyst and 2 fibroadenoma) and seven normal breast tissue
samples adjacent to ductal carcinoma in situ (DCISN for DCIS-adjacent normal). In this
independent test set, we applied the same normalization, data preprocessing algorithms and
parameters as were applied to the training set. Of the 200 probes that comprised our classifier
in the training set, 149 were present with >80% good data in this second independent test set.
All 3 of the normal tissues adjacent to benign lesions were classified as RM-like and 4 of 7
DCISN samples were identified as cancer-adjacent normal. These results suggest that the
normal breast signature that we observed in RM is not peculiar to women who elect reduction
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surgery, and furthermore, documents that the CN-like signature is also present adjacent to DCIS
in some patients, even before the disease becomes invasive.
Because Chang et al. had previously published a serum treatment/wound response signature
(15), we were interested in whether their in vitro signature, which had little overlap in terms
of exact gene content, but substantial overlap in terms of the processes represented, would also
predict CN vs. RM status. We classified each of our samples as ‘Activated’ or ‘Quiescent’
using their signature and classification parameters, expecting that perhaps ‘Activated’ would
be more common in the CN samples. However, approximately 37% percent of RM samples
were classified as ‘Activated’ and 35% of CN samples were classified as ‘Activated’,
demonstrating that the in vitro serum response signature does not offer predictive value in
distinguishing RM and CN samples (Chi square test, 1 df, p=0.8). This suggests that while
many of the processes involved in wound response may be common to different experimental
and observational systems, the specific signatures of wound response may be tissue/ and or
cell-type dependent. Our wound response signature, being breast tissue derived, appears to
offer advantages over the in vitro serum-derived signatures in identifying abnormal breast
tissues.
In Vivo Wound Response and Patient Survival
Because the aforementioned signature derived from serum-treated fibroblasts, commonly
referred to as the “wound response” signature, was highly prognostic for breast cancer patient
outcomes, we hypothesized that our in vivo, 200-probe, breast tissue-derived wound response
signature might also have prognostic value. Thus we evaluated the prognostic value of our
signature on a test set of 295 patients from the Netherlands Cancer Institute (NKI) (15,34).
These 295 patients were divided into three groups based on the rank order of the first principal
component of our in vivo wound response signature across their tumor expression profiles
(gene expression shown in Figure 2) and we conducted Kaplan-Meier analysis to evaluate the
association between these groups and overall and relapse free survival (Figure 3).
In Figure 2, the poor prognosis group (Group I) had low expression of immediate early genes
CTGF and CYR61 and low expression of GREM1 and GREM2. GREM1 is an important
developmental signaling molecule that is part of an FGF/GREM1 inhibitory loop that halts
tissue outgrowth during development and regeneration (35). These tumors also have low
expression of angiogenesis inhibitor THBSP1 (36). In contrast, the good prognosis group III
tumors had high expression of these same genes. The Group I poor prognosis tumors had high
expression of a number of chemotaxis and immunoregulatory genes including IL-1β, TLR2,
CCL2, and indoleamine 2,3-dioxygenase, a targetable enzyme that modulates the response of
T-cells to tumors (37). These tumors have high expression of Keratin 6 and 14, the former of
which contains an IL-1 responsive DNA element (38). Keratin 6 is expressed in the skin in
hyperproliferative disorders and in response to stressful stimuli such as wounding (29). Keratin
14 (K14) is a basal keratinocyte marker that is differentially expressed in wound repair (30).
We observed that basal-like tumors were more likely to have the Group I wound response
signature, while luminal tumors were more likely to be Group III (Figure 2). The correlations
between subtype and some of the gene expression changes were consistent with those in
previous studies. For example, PTGS2 has been shown to be highly expressed in basal-like
tumors (39) previously, and we also observed this here.
Based on the three groups of equal size identified in Figure 2, we then evaluated associations
with survival. The three groups had different relapse free (Figure 3A) and overall survival
(Figure 3B) and the predictive value of these signatures compare favorably with other
prognostic signatures that have used microenvironment biology to predict outcome. For
example, our signatures show prognostic value similar to that provided by the Chang et al.
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wound response signature in predicting relapse free (Figure 3C) and overall (Figure 3D)
survival.
To further evaluate concordance of our in vivo wound response with previous wound response
or microenvironment-related signatures we applied methods described in Fan et al. (34).
Concordance between predictors was evaluated by classifying each patient and then conducting
a Chi-square test to identify associations between classifications made by each predictor. Table
1 shows that there was high concordance between those classified as “activated” by Chang et
al, and our Group I and II tumors. Likewise, our predictor showed significant concordance
with the three-class SDPP predictor (21) and DTF signatures (22), both of which were more
likely to classify group III tumors as good prognosis and group I tumors as poor prognosis.
While our signature represents many of the processes observed to occur in healing skin (32),
we sought to strengthen the claim that our signature reflects wound repair using results from
previous gene expression studies of healing skin and wound response in breast. Using the same
concordance evaluation methods (34) that we applied for SDPP and DTF signatures, we found
a significant association between our signature and a previously published gene expression
signature for the early response of skin to injury (40). This signature was measured only 30 or
60 minutes after skin injury, so does not reflect chronic injury and it is also derived from skin
not breast. Thus, we also sought comparisons with breast tissue injury. A breast injury signature
has not been reported, but mammary gland involution has established features of wound repair
(41). Therefore we examined concordance with the mammary gland involution signature and
found a strong and significant correlation. The results are presented in Table 1. Taken together,
these findings show reproducible concordance between our signature and wound repair- and
microenvironment-based signatures.
DISCUSSION
It has been argued that solid tumors are composed of two distinct but interdependent
compartments: the malignant parenchyma and its supporting microenvironment (42). In this
paper, we have studied how the normal microenvironment responds to the presence of the
tumor. Our results show that a wound response signature is activated in the histologically
normal tissue of cancer patients. Wound healing includes numerous overlapping processes
such as blood clotting, inflammation, extracellular matrix alterations, angiogenesis, and tissue
remodeling [reviewed in (2,32)]. Many of these processes are expressed differentially in normal
tissue adjacent to breast cancer and in tumors, but not in the normal tissue of women undergoing
reduction mammoplasty.
Previous microarray studies have examined molecular similarities between wound repair and
cancer using in vitro models. First, Iyer et al. studied the response of fibroblasts to serum
(43), based on the idea that serum has a very specific meaning in vivo: cells encounter serum
only in the event of local injury. In response, tissues mount a rapid, concerted multicellular
response to preserve tissue integrity. Serum promotes growth and survival of normal and cancer
cells in culture, and in parallel, serum causes rapid cell proliferation in tissue-level wound
repair responses. Given these parallels, Iyer et al. were able to document a serum response of
foreskin fibroblasts that included genes involved in clotting and coagulation during
remodeling, including tissue factor 3 (TF3), genes promoting migration and proliferation of
fibroblasts (e.g. CTGF), and genes involved in angiogenesis (e.g. COX2 and IL1β). Many of
these same genes were modified in our in vivo wound response signature. To extend the
observations of Iyer et al., Chang et al. hypothesized that a canonical gene expression signature
might be identified for serum response of fibroblasts from different anatomic sites (15). Using
gene expression profiles of 50 samples from ten sites, Chang et al. recapitulated a wound
response signature originally reported by Iyer et al. and documented that this Core Serum
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Response (CSR) was evident in a subset of breast tumors. Breast tumors that expressed the
serum response signature had a poorer prognosis than tumors with a ‘quiescent’ serum response
phenotype. While the in vitro wound response signatures of Iyer et al. and Chang et al. did not
have predictive accuracy in distinguishing RM and CN tissues in our dataset, we did observe
that the same biological processes are activated in association with breast cancer in vivo, outside
the boundaries of the tumor itself.
The association between microenvironment characteristics, survival and breast cancer subtype
has been reported in previous papers. For example, in a tissue microarray study of 479 invasive
breast carcinomas using 28 different markers, basal-like breast cancers were more likely to
highly express genes (such as laminin) that are involved in ECM remodeling (44). In a separate
study, the ECM composition of 28 primary breast carcinomas were examined using
microarrays and a gene expression profile of 278 ECM-related genes were used to divide the
tumors into four main groups that correlated with outcome and basal-like subtype (45). The
current results confirm that many ECM genes are enriched in basal-like cancers and that these
genes have prognostic value, but suggest that the enrichment may be part of a broader, chronic
response of the host as it attempts to repair the tissue injury caused by cancer.
Strengths of our investigation include the large number of samples relative to previous studies
of histologically normal tissue, the application of methods to control for confounding by age,
and the systematic comparison with previous microenvironment-derived signatures.
Additionally, we documented the generalizability of our findings to women with premalignant
or benign breast disease and showed the validity of our predictor in two independent test sets.
Our results demonstrate that use of whole tissue, which includes epithelial cells as well as
stromal cells, does not hamper our ability to detect important microenvironment signatures.
Many of the genes we detected as differentially expressed are reported to be expressed by
fibroblasts (e.g. CTGF) and neutrophils (e.g. IL1B) for example, while others are epithelial
contributors (keratins 6 and 14). This reiterates the findings of Perou et al. (46) showing that
signatures from distinct cellular compartments can be identified in microarray data from mixed
cell populations.
Our results suggest some important questions for future investigation related to the spatial and
temporal parameters of the wound response to cancer. While our tissue procurement protocols
ensured that the histologically normal tissue was collected from regions outside of tumor
margins, the distance to the margin was not measured precisely so we are unable to document
the geographic zones of gene expression alterations. Methylation changes have been reported
as far as 4 cm from the site of the primary tumor (47), however the geographic zones for gene
expression alterations have not been characterized. Based on the notion that wound response
is a local phenomenon, it might be expected that the wound response would not be present in
contralateral breast, or that it may dissipate as the distance from the primary tumor increases,
but this has not been investigated. The geographic limits of the wound response to cancer may
have translational implications. For example, most tumor recurrences occur at the site of
previous resection even when margins are clear (48). If gene expression alterations with
promoting characteristics have a defined range of action outside the primary tumor margins,
future guidelines for surgical intervention may need to consider wider margins consistent with
the geographic range of microenvironment alterations. It is also not known how early in
development of breast cancer gene expression alterations are activated in adjacent normal
tissue. Leukocyte infiltration occurs early in carcinogenesis (49), suggesting that aberrations
in gene expression may already be present during DCIS, but this has not been investigated.
What is clear from our results is that wound response signatures are strongly activated in
histologically normal tissue adjacent to invasive tumors.
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A role for wound response in breast carcinogenesis is increasingly well documented.
Differential expression of wound response signatures in different tumors suggests that
individualized targeting of microenvironment may be a viable treatment strategy in breast
cancer. For example, there is significant heterogeneity in extracellular matrix across tumors
(44,45) suggesting differential efficacy of ECM targeting drugs. The strong angiogenesis
signature observed in Group I tumors, which are enriched for basal-like breast cancers, supports
the application of chemotherapy combinations that target VEGF and angiogenesis in triple
negative breast cancers (50). By better characterizing microenvironment heterogeneity,
improved strategies for application of novel and existing therapies may be possible. The
similarities between cancer and wound response are compelling and continued investigation
of host responses to cancer may lead to new biological insights and translational opportunities.
Acknowledgments
The authors are grateful to Dr. Melissa Johnson, Dr, Kristin Stueber, and Christina Alves Baghat, PA, and pathologist
Dr. Giovanna Crisi at Baystate Medical Center and to Dr. Lisa Carey, Emily Burrows, Amy Drobish, and pathologists
Chad Livasy and. Leigh Thorne at University of North Carolina Hospitals. We are grateful to Dr. Keith Amos for
helpful comments on this manuscript. Funding for the study was from grant #IRG 93-033 from the American Cancer
Society, from the National Institutes of Environmental Health Sciences (R01 ES015739-01), the National Cancer
Institute (R01CA138255-01), Avon Foundation, and the North Carolina University Cancer Research Fund.
References
1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound
healing. N Engl J Med 1986;315:1650–1659. [PubMed: 3537791]
2. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell
Biol 2008;9:628–638. [PubMed: 18628784]
3. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases
as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227–239. [PubMed:
16498445]
4. Yamaguchi Y. Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer
2007;14:175–181. [PubMed: 17485903]
5. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer
2007;7:139–147. [PubMed: 17218951]
6. Kenny PA, Lee GY, Bissell MJ. Targeting the tumor microenvironment. Front Biosci 2007;12:3468–
3474. [PubMed: 17485314]
7. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in
breast cancer. Cancer Cell 2004;6:17–32. [PubMed: 15261139]
8. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46–54. [PubMed:
11900251]
9. Gusterson BA, Warburton MJ, Mitchell D, et al. Distribution of myoepithelial cells and basement
membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res
1982;42:4763–4770. [PubMed: 6290045]
10. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to
malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69–125. [PubMed:
8592733]
11. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development:
extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast.
Breast Cancer Res 2003;5:130–135. [PubMed: 12793893]
12. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their
origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia
2005;10:261–272. [PubMed: 16807805]
13. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer
Res 2006;66:605–612. [PubMed: 16423985]
Troester et al. Page 10













14. Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast
tissue identify basal-like tumors. Breast Cancer Res 2006;8:R58. [PubMed: 17054791]
15. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response
predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
[PubMed: 14737219]
16. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray
platforms. BMC Genomics 2006;7:96. [PubMed: 16643655]
17. Tan Q, Zhao J, Li S, et al. Differential and correlation analyses of microarray gene expression data
in the CEPH Utah families. Genomics. 2008
18. Benito M, Parker J, Du Q, et al. Adjustment of systematic microarray data biases. Bioinformatics
2004;20:105–114. [PubMed: 14693816]
19. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival
in breast cancer. N Engl J Med 2002;347:1999–2009. [PubMed: 12490681]
20. van ’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome
of breast cancer. Nature 2002;415:530–536. [PubMed: 11823860]
21. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer.
Nat Med. 2008
22. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust
stromal response in breast carcinoma. Lab Invest. 2008
23. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol
2004;31:22–29. [PubMed: 15179621]
24. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible
immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A
1998;95:6355–6360. [PubMed: 9600969]
25. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial
cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and
induces angiogenesis in vivo. Mol Cell Biol 1999;19:2958–2966. [PubMed: 10082563]
26. Shimo T, Nakanishi T, Nishida T, et al. Connective tissue growth factor induces the proliferation,
migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J
Biochem 1999;126:137–145. [PubMed: 10393331]
27. Chen CC, Mo FE, Lau LF. The angiogenic factor Cyr61 activates a genetic program for wound healing
in human skin fibroblasts. J Biol Chem 2001;276:47329–47337. [PubMed: 11584015]
28. Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cyclooxygenase-2 in human mammary
epithelial cells and is activated in premalignant tissue. Cancer Res 2005;65:1792–1799. [PubMed:
15753376]
29. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation
cycle. J Invest Dermatol 2001;116:633–640. [PubMed: 11348449]
30. Hosoya A, Lee JM, Cho SW, et al. Morphological evidence of basal keratinocyte migration during
the re-epithelialization process. Histochem Cell Biol 2008;130:1165–1175. [PubMed: 18773217]
31. Bernot KM, Coulombe PA, McGowan KM. Keratin 16 expression defines a subset of epithelial cells
during skin morphogenesis and the hair cycle. J Invest Dermatol 2002;119:1137–1149. [PubMed:
12445204]
32. Martin P. Wound healing--aiming for perfect skin regeneration. Science 1997;276:75–81. [PubMed:
9082989]
33. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer
Cell 2008;13:394–406. [PubMed: 18455123]
34. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast
cancer. N Engl J Med 2006;355:560–569. [PubMed: 16899776]
35. Verheyden JM, Sun X. An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud
outgrowth. Nature 2008;454:638–641. [PubMed: 18594511]
36. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53
regulation of thrombospondin-1. Science 1994;265:1582–1584. [PubMed: 7521539]
Troester et al. Page 11













37. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine
2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer
chemotherapy. Nat Med 2005;11:312–319. [PubMed: 15711557]
38. Komine M, Rao LS, Freedberg IM, et al. Interleukin-1 induces transcription of keratin K6 in human
epidermal keratinocytes. J Invest Dermatol 2001;116:330–338. [PubMed: 11180011]
39. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS
associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell
2007;12:479–491. [PubMed: 17996651]
40. Cole J, Tsou R, Wallace K, Gibran N, Isik F. Early gene expression profile of human skin to injury
using high-density cDNA microarrays. Wound Repair Regen 2001;9:360–370. [PubMed: 11896979]
41. Stein T, Morris JS, Davies CR, et al. Involution of the mouse mammary gland is associated with an
immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res
2004;6:R75–91. [PubMed: 14979920]
42. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J
Pathol 2003;162:1747–1757. [PubMed: 12759232]
43. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts
to serum [see comments]. Science 1999;283:83–87. [PubMed: 9872747]
44. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast
cancer relates to the basal-like phenotype. Cancer Res 2008;68:989–997. [PubMed: 18281472]
45. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer
subgroups with different clinical outcome. J Pathol 2008;214:357–367. [PubMed: 18044827]
46. Perou CM, Brown PO, Botstein D. Tumor classification using gene expression patterns from DNA
microarrays. New Technologies for life sciences: A Trends Guide 2000:67–76.
47. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic
biomarkers in normal breast tissue. Clin Cancer Res 2006;12:6626–6636. [PubMed: 17121881]
48. Dalberg K, Mattsson A, Sandelin K, Rutqvist LE. Outcome of treatment for ipsilateral breast tumor
recurrence in early-stage breast cancer. Breast Cancer Res Treat 1998;49:69–78. [PubMed: 9694613]
49. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer
development. Nat Rev Cancer 2006;6:24–37. [PubMed: 16397525]
50. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston
Park) 2008;22:1233–1239. [PubMed: 18980022]discussion 1239–1240, 1243
Troester et al. Page 12













Figure 1. Wound response signatures are differentially expressed between reduction mammoplasty
patients (RM) and histologically normal tissue of cancer patients (cancer normal, or CN)
Figure A shows the complete dendrogram for 200 probes that distinguish RM from CN tissues
with 98% accuracy in predictive analyses. The dendrogram in B shows CN samples (red) and
RM samples (green) form distinct branches, with only a few CN tissues clustering with RM
samples. The clusters show that various biological processes involved in wound repair are
differentially expressed between the two groups, including extracellular matrix alterations (C
& D), immediate early (IE) genes involved in angiogenesis (E), Re-epithelialization and celluar
adhesion (F), and cellular adhesion and chemotaxis (G). Supplemental Table 1 lists log2(R/G)
values for each sample by probe ID and Supplemental Table 2 provides DAVID analysis results
for the 200 probe gene set.
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Figure 2. Differential expression of wound response signatures in breast cancer
Expression of our in vivo wound response signature (Figure 1) was examined in 295 tumors
from the Netherlands Cancer Institute (15). Principal Component Analysis was used to divide
the samples into three groups of equal size (Groups I, II, and III) and the samples are ordered
according to their assigned Group. ER status is indicated (gray = ER negative, black= ER
positive), along with breast cancer subtype (red = basal-like, magenta=HER2-enriched, light
blue = luminal B, dark blue = luminal A, green = normal-like). Two gene clusters were
identified: one where low expression predicted poor outcome and one where high expression
predicted poor outcome.
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Figure 3. In vivo wound response signature and previously published serum response signature
show similar prognostic value
Kaplan-Meier analyses were conducted using the PCA-assigned Group I, II, or III (A and B)
and using the Chang et al. core serum response assignments (C and D). Both classification
schemes are associated with overall and relapse free survival.
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